Among MET-positive patients , higher rilotumumab exposure , vs placebo and low exposure , was associated with improved median PFS ( 80 % CI : 7.0 ( 5.7-9 .7 ) vs 4.4 ( 2.9-4 .9 ) and 5.5 ( 4.2-6 .8 ) months ) and OS ( 13.4 ( 10.6-18 .6 ) vs 5.7 ( 4.7-10 .2 ) and 8.1 ( 6.9-11 .1 ) months ) without increased toxicity .